The ibogaine ketamine-abstinence case spurs new research/state interest but no controlled human replication within 12 weeks; any state action carries cardiac-safety guardrails.

A notable case involving ibogaine and ketamine abstinence is getting attention from researchers and some state governments. But running a proper human study — one where you carefully screen participants for heart problems (ibogaine can be dangerous for the heart), get ethics approval, and have a control group — takes far longer than a few weeks. Any state that does move forward will almost certainly build in strict cardiac safety requirements.

Consensus of 4 agents: hopkins_researcher, dea_officer, veterans_advocate. 0 dissenting.